Sadia Sikder

Sadia Sikder

Auto-generated profile, based on publicly available information

Sadia Sikder

Division of Pharmacological & Pharmaceutical Sciences, University of Missouri Kansas City , Kansas , MO , USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
Vrinda GoteVrinda Gote
Vrinda Gote
SSSadia Sikder
Sadia Sikder
JSJeff Sicotte
Jeff Sicotte
DPDhananjay Pal
Dhananjay Pal
Ocular drug delivery has always been a challenge for ophthalmologist and drug delivery scientists due to presence of various anatomical and physiological barriers. Inimitable static and dynamic ocular barriers not only exclude the entry of xenobiotics but also discourage the active absorption of therapeutic agents. An ideal drug delivery system should be designed to enhance drug bioavailability, provide controlled and sustained release of drug at site of action and overcome various ocular barriers. Conventional ophthalmic medications includes the use of topical eye drops and intravitreal injections of anti-VEGF agent for treatment of anterior and posterior segment disorders respectively. Current inventions for the anterior ocular segment disorders like punctum plugs, ocular implants, drug eluting contact lenses, and ocular iontophoresis represent state of the art inventions for sustained and controlled drug release. Parallel efforts for ocular drug delivery technologies for back of the eye disorders have resulted in the approval of various intravitreal implants. Novel drug delivery technologies including nanoparticles, nanomicelles, dendrimers, microneedles, liposomes and nanowafers are increasingly studied for anterior and posterior disorders. To achieve patient compliance for back of the eye disorders, novel approaches for noninvasive delivery of potent therapeutic agents are on a rise. In this review article we discuss the past successes, present inventions and future challenges in ocular drug delivery technologies. This expert opinion also discusses the future challenges for ocular drug delivery systems and the clinical translatable potential of nanotechnology from benchtop to the bedside. SIGNIFICANCE STATEMENT N/A

17 July 2019 in AAPS PharmSciTech
Verified
Journal Article
Closed access
MAMeshal Alshamrani
Meshal Alshamrani
SSSadia Sikder
Sadia Sikder
FCFohona Coulibaly
Fohona Coulibaly
AMAbhirup Mandal
Abhirup Mandal
DPDhananjay Pal
Dhananjay Pal
AMAshim Mitra
Ashim Mitra

16 September 2019 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
SSSadia Sikder
Sadia Sikder
VGVrinda Gote
Vrinda Gote
MAMeshal Alshamrani
Meshal Alshamrani
JSJeff Sicotte
Jeff Sicotte
DPDhananjay Pal
Dhananjay Pal
Introduction: Proteins and peptides are prominent therapeutic agents, which are effective in number of ailments. Long-term delivery of protein- and peptide- therapeutics requires polymeric encapsulation to protect from degradation and for its sustained release. However, results from encapsulation of protein macromolecules in dynamic delivery systems report unreliable clinical outcome, indicating ease of degradation, low permeability and serious immune responses. A specifically targeted delivery system as tumor or cancer theranostics may surpass these limitations. Areas covered: This review covers recent advancements in approaches involving conjugated protein nano-formulations as targeting delivery technology for various ailments encompassing mostly cancer treatment options. Progressions in targeted chemotherapeutics, protein nanoparticles, peptide nanoparticles, lipidation and antibody drug-conjugates are discussed. Expert opinion: Significant expansion have been made in forming new generation of antitumor-recombinant proteins, which proves a milestone of advancements for more potent and explicit cancer therapies. However, transformation of biologics from laboratory to clinical trials is an immense challenge, because of drop in efficiency of drug-loading, poor reproducibility of nanoparticles, inadequate information regarding long term toxicity and insufficient pharmacokinetics data. Hence, early stage tumor diagnosis with précised drug delivery to tumor site is crucial for protein- and peptide- based therapeutics for cancer.